ZIOP - ZIOPHARM Oncology, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

ZIOPHARM Oncology, Inc.

Parris Building 34
Navy Yard Plaza One First Avenue
Boston, MA 02129
United States
617-259-1970
http://www.ziopharm.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees48

Key Executives

NameTitlePayExercisedYear Born
Dr. Laurence James Neil CooperCEO & Director1.59MN/A1965
Dr. David M. Mauney M.D.Pres608.76kN/A1969
Mr. Kevin G. LafondSr. VP of Fin., Chief Accounting Officer & Treasurer399kN/A1956
Mr. Robert HadfieldExec. VP, Gen. Counsel, Sec. & Chief Compliance Officer376.7kN/A1978
Ms. Lynn M. FerrucciExec. VP of HR, Facilities, Admin. & ITN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, to treat patients with recurrent glioblastoma and breast cancer. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; research and development agreement with the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.

Corporate Governance

ZIOPHARM Oncology, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 5. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 2; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.